

Conflict of Interest in Oncology Publications

A Survey of Disclosure Policies and Statements

Aaron S. Kesselheim, MD, JD, MPH; Joy L. Lee, MPH; Jerry Avorn, MD; Amber Servi, BA; William H. Shrank, MD, MSHS; and Niteesh K. Choudhry, MD, PhD

BACKGROUND: Disclosure of conflicts of interest in biomedical research is receiving increased attention. The authors sought to define current disclosure policies and how they relate to disclosure statements provided by authors in major oncology journals. **METHODS:** The authors identified all oncology journals listed in the Thomson Institute for Scientific Information and sought their policies on conflict-of-interest disclosure. For a subset of journals with an Impact Factor >2.0, they catalogued the number and type of articles and the details of the published disclosures in all papers from the 2 most recent issues. **RESULTS:** Disclosure policies were provided by 112 of 131 journals (85%); 99 (88%) of these requested that authors disclose conflicts of interest (mean Impact Factor for these journals: 4.6), whereas the remaining 13 (12%) did not (mean Impact Factor: 2.9). Ninety-three journals (94%) required financial disclosure, and 42 (42%) also sought nonfinancial disclosures. For a subset of 52 higher-impact journals (Impact Factor >2.0), we reviewed 1734 articles and identified published disclosures in 51 journals (98%). Many of these journals (31 of 51, 61%) included some disclosure statement in >90% of their articles. Among 27 journals that published editorials/commentaries, only 14 (52%) included disclosures with such articles. There was no publication of any nonfinancial conflicts of interest in any article reviewed. **CONCLUSIONS:** Disclosure policies and the very definition of conflict of interest varied considerably among journals. Although most journals had some policy in this area, a substantial proportion did not publish disclosure statements consistently, with deficiencies particularly among editorials and commentaries. *Cancer* 2012;118:188-95. © 2011 American Cancer Society.

KEYWORDS: conflict of interest, disclosure, publishing, clinical oncology.

Researchers, clinicians, and the public are increasingly concerned about the potential for investigators' financial relationships to create conflicts of interest in the conduct or reporting of biomedical research.¹ There is growing evidence about the possible effects of these conflicts; sources of financial support have been shown to have an impact on the design² and outcomes³ of trials and on the reporting of results⁴ in many medical fields,⁵⁻⁸ including oncology.⁹ Because eliminating potential conflicts of interest is essentially impossible and may even be harmful,¹⁰ nearly all biomedical journals manage this issue by requiring authors to disclose funding for their work, as well as other relevant relationships that they, their families, or their institutions might hold when an article is submitted for publication.¹¹ Certain disclosure policies have been shown to affect the presentation of published articles.¹²

In some cases, researchers have not been forthcoming about potential financial conflicts. For example, a trial about use of computerized tomography to help detect lung cancer in smokers listed substantial funding from a nonprofit foundation that, 2 years later, was revealed to have close financial ties to a major cigarette manufacturer.¹³ Medical journals, for their part, have been criticized for publishing articles without fully disclosing or adequately accounting for financial relationships of authors, such as in supplements wholly sponsored by pharmaceutical manufacturers.^{14,15}

As a result, many journals have re-examined their conflict of interest disclosure practices in recent years. In 2009,¹⁶ the International Committee of Medical Journal Editors promulgated new standards (revised in 2010),¹⁷ including a uniform disclosure template that requires authors to disclose direct support for the research, personal financial relationships including honoraria, stock options and patents, and other interests authors might have related to their work. Despite these advances, biomedical journals still have a range of disclosure practices. Recent studies of journals with high Impact Factors

Corresponding author: Dr. Aaron S. Kesselheim, MD, JD, MPH; Division of Pharmacoepidemiology and Pharmacoeconomics, 1620 Tremont St., Suite 3030, Boston, MA 02120; Fax: (617) 232-8602; akesselheim@partners.org

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

DOI: 10.1002/cncr.26237, **Received:** December 10, 2010; **Revised:** March 23, 2011; **Accepted:** April 8, 2011, **Published online** June 29, 2011 in Wiley Online Library (wileyonlinelibrary.com)

identified substantial variation in disclosure requirements and in how conflict of interest is defined in cardiology, across medical specialties, and in pediatrics.¹⁸⁻²⁰

In the field of cancer research, financial relationships and other conflicts of interest of biomedical researchers have been particularly contentious.^{21,22} Previous studies have identified frequent reports of conflicts of interest in papers published in high-impact journals.^{23,24} To more comprehensively define the current status of journal disclosure practices in this field, we collected information related to conflict of interest disclosure from all oncology journals. We also examined the disclosures accompanying papers published in these journals to compare the nature of requested information with information that is provided alongside published research.

MATERIALS AND METHODS

Sources of Data

We identified all oncology-related medical journals using the Thomson Institute for Scientific Information's Web of Science. From September to December 2009, we searched each journal's official website and copied the entire author submission guidelines. Any separate documents related to manuscript submission were downloaded and compiled into a single complete record. Journals that did not provide author submission information on their website were contacted by email (on 2 separate occasions, as necessary) to request all guidelines or forms from an editor.

We then selected a subset of these oncology journals for more detailed investigation of the published disclosures through an analysis of published articles. We limited this analysis to all journals from our original sample with an Impact Factor >2.0 based on the 2008 Impact Factor published by the Thomson Institute for Scientific Information Journal Citation Reports. Impact Factor is a ratio of the number of citations in the current year to items published by a journal in the previous 2 years (the numerator) and the number of substantive articles published by that journal in the last 2 years (the denominator).²⁵ We used Impact Factor because this measure has been found to be the strongest predictor of an article's subsequent dissemination.²⁶ In addition, articles from journals with higher Impact Factors have been preferentially cited in government-developed practice guidelines, which are intended to influence physician behavior.²⁷ Finally, focusing on the highest-impact journals allowed us to more easily obtain full access to these journals through pre-existing

institutional library electronic or print subscriptions. In this analysis, we acquired each article from the 2 most recent issues preceding the date that we obtained their disclosure policy (date range: June-December 2009) and copied any published author disclosures from all research articles, reviews, and commentaries/editorials.

Study Instruments

Design of the instrument for recording information about disclosure policies was informed by review of the literature and a preliminary review of the disclosure requests from 5% of the journals in this sample. The information collected fell into 3 categories. First, we noted characteristics of the journal, including its country of origin, Impact Factor, and whether it was a member of a publishing group (eg, Nature, Elsevier). We identified whether the journal had a disclosure requirement statement, the word length and reading level of that disclosure statement, and the existence (if any) of a preprinted form. Reading level was assessed using the Flesch-Kincaid Grade Level, which is a reliable and valid tool that uses word and sentence length to determine the school-grade reading level of text.²⁸ Reading level is a proxy for the understandability of the forms and the ease with which they can be completed. These factors may influence the substance of disclosures, even for highly educated individuals. Next, we extracted general features of the disclosure policy, including its definition and scope, specific mention of funding source or ghostwriting, the particulars of publication of the disclosure, and penalties for nondisclosure. Finally, we identified disclosure descriptors, including types of financial and/or nonfinancial relationships and mention of particular dollar figures or date ranges.

The instrument for recording the content of published disclosures followed a similar structure. We catalogued the number and type of articles (eg, original research, editorial) and the location of the printed disclosure (if any). If a disclosure was included with the article, we noted which disclosure descriptors were included. So as not to overemphasize journals that published a relatively large number of articles per issue, we set our unit of analysis as the journal (rather than the article). If any article within the 2 issues we analyzed included an author disclosure, that journal was registered as publishing this descriptor.

Data Extraction

Each journal's author disclosure requirements and content of printed disclosures were evaluated separately by 2




Figure 1. Definitions of conflict of interest in oncology journals are shown. Each segment refers to a different nonmutually exclusive definition of potential conflicts of interest provided by oncology journals (total N = 131).

authors (A.S.K., A.S., J.L.L., or N.K.C.). For journals' definitions of the basic scope of disclosure, which were a primary outcome (Fig. 1) and required subjective assessment on the part of the coders, we assessed the level of interobserver agreement by calculating a kappa statistic, which is a measure of the level of agreement beyond chance. For classifying a journal's disclosure policy as including information that could lead to author embarrassment, the kappa was 0.84. For classifying a journal's disclosure policy as including information that could lead to the results being biased, the kappa was 0.75. For classifying a journal's disclosure policy as including information relating to outside benefits earned by the authors, the kappa was 0.64. These results indicate good-to-excellent interobserver agreement²⁹ and are comparable to results from previously published descriptive research in this field.²⁴ All differences were resolved by consensus. We used Excel 2003 (Microsoft, Redmond, Wash) for descriptive analyses.

RESULTS

We identified 131 oncology-related journals and were able to obtain information about disclosure policies from 112 (85%) of them. Ninety-nine (88%) of these journals requested author disclosures, whereas the remaining 13 either did not request disclosures from authors or did not have disclosure policies (see Table 1). Journals in this latter category had a relatively low mean Impact Factor (2.9) and were most likely to be based in Europe (54%) and

Table 1. Characteristics of Oncology Journals Studied

Characteristic	Journals Requiring Disclosure, n=99	Journals With No Policies, n=13
Impact factor, mean [SD]	4.6 [2.5-6.7]	2.9 [1.7-3.1]
Issues per year, median {IQR}	12 {6-12}	12 {12-12}
Geographic location, No. (%)		
US	46 (46%)	4 (31%)
UK	14 (14%)	0 (0%)
Europe	25 (25%)	7 (54%)
Other	14 (14%)	2 (15%)
ICMJE member, No. (%)	10 ^a (10%)	0 (0%)
Publishing group member, No. (%)	81 (82%)	11 (85%)
Clinical topic, No. (%)		
General oncology	39 (39%)	5 (38%)
Oncologic basic science	22 (22%)	5 (38%)
Specialized		
Subspecialty	19 (19%)	1 (8%)
Surgical oncology	4 (4%)	0 (0%)
Radiation oncology	4 (4%)	1 (8%)
Other	11 (11%)	1 (8%)

Abbreviations: ICMJE, International Committee of Medical Journal Editors; IQR, interquartile range; SD, standard deviation.

Total N = 131. No information on disclosure policies could be obtained for 19 journals (15%).

^aDoes not include 3 journals that referred to ICMJE policies but were not registered with the ICMJE.

have a thematic focus on oncologic basic science (38%). The data extracted from the sample of 99 journals that requested author disclosures formed the sample for our analysis of disclosure policies.

Author Disclosure Policies

Characteristics of disclosure policies

Among journals that sought author disclosures, 56 (57%) had individualized disclosure policies, 40 (40%) had disclosure policies derived from a larger family of journals (eg, Elsevier, Nature group, American Association for Cancer Research), and 3 (3%) had a general statement that referred to the current International Committee of Medical Journal Editors guidelines. Thirty-seven (37%) had separate forms related to disclosure, whereas the remainder (63%) requested that authors include a free-form disclosure statement along with their manuscript. The combined disclosure statements and forms averaged 360 words and were at a 13.8 grade reading level.

A minority of journals took additional steps to describe the disclosure process in more depth. Thirty-four (34%) provided a descriptive rationale for why their policy was important. Eleven journals (11%) provided




Figure 2. Prevalence of specific financial and nonfinancial disclosure requests and printed disclosures in oncology journals is shown. The black bars show the frequency of specific disclosure requests in the categories listed ($n = 99$), whereas the hatched bars show frequency of reported disclosures appearing in 2 sequential issues in our subsample of journals with Impact Factor >2.0 ($n = 52$).

comments that disclosures were routine or that they would not automatically lead to a manuscript's rejection; 13 (13%) specified penalties for failure to disclose a relevant relationship. Twelve journals (12%) promised that disclosures would be kept confidential, and 8 (8%) noted that disclosures would not be shared with peer reviewers. Finally, 39 (39%) described some features of how a disclosure might be published in conjunction with an accepted manuscript.

Definitions of disclosure

Sixty-seven journals (68%) made some reference to the types of outside relationships that would qualify for disclosure, although only 50 (51%) explicitly defined the term *conflict of interest*. Concerning relationships were most commonly described in 1 of 3 nonmutually exclusive categories: those that could bias conclusions or influence the integrity or objectivity of the author (51, 52%), those with companies that could stand to gain from the outcome of the trial (24, 24%), and those that could embarrass the author (13, 13%) (Fig. 1). A minority of journals (13, 13%) recommended erring on the side of caution when deciding what to disclose. Nearly half of the journals explicitly limited disclosures to the author (48, 49%), whereas smaller numbers also requested potential relationships from authors' families (12, 12%), institutions (10, 10%), or both (3, 3%). The remaining 26 journals (26%) did not specify the relevant parties for disclosure purposes.

Specifics of financial versus nonfinancial disclosures

Ninety-three journals (94%) specifically requested financial disclosures, and although no journal requested the particular amount, 11 (11%) provided guidance for what should be considered a relevant monetary disclosure. For example, 1 journal suggested that a \$10,000 financial interest was relevant for employment, stocks, and patents, \$20,000 for research funding, and \$5000 for honoraria, manuscript fees, or other gifts. A minority of journals, 42 (42%), also sought nonfinancial disclosures. Journals provided a number of different examples of the types of financial and nonfinancial disclosures authors should disclose (Fig. 2). Twenty-nine (29%) specified the time frame for lapsed relationships (median 3 years, interquartile range, 3-3), and even fewer (11, 11%) requested information about planned or future relationships. Finally, a small number of journals (27, 27%) asked whether any authors were paid to write the manuscript without participating in the research (ghostwriting), and a similar number (30, 30%) asked for details about the role of the funding source.

Characteristics of Published Disclosures

From the sample of 99 journals that required disclosure, 68 qualified for further review (Impact Factor >2.0), and we obtained full copies of 2 issues of 52 (76%) of the journals in this group. We reviewed 1734 articles from these




Figure 3. Proportion of articles in high-impact oncology journals that contain any disclosure statement is shown. Disclosures included both statements of potential conflicts of interest and statements that no conflicts existed. Total N = 51.

journals (an average of 17 original articles per issue, including an average of 0.7 editorials/commentaries). We identified printed disclosures in 51 of the 52 (98%) journals. The dominant location (40, 78%) for appearance of the published disclosure was after the text of the article. The remainder placed the disclosures on the first page (4, 8%), both on the first page and after the text (5, 10%), or after the references (2, 4%). Among these 51 journals, nearly two-thirds (31 of 51, 61%) included some disclosure statement (including reports of financial interests or a printed statement confirming lack of conflicts) in >90% of the articles they published. The remainder included disclosure statements in smaller fractions of their articles (Fig. 3); 1 journal included a disclosure statement of any kind in only a single article in the issues we reviewed. Rates of disclosure statements differed between reports of research and editorials/commentaries. Among the 27 journals that published editorials/commentaries, only 14 (52%) included disclosures along with that content.

Although 51 journals included at least 1 disclosure relating to research grants, the prevalence of other published descriptors was much smaller (Fig. 2). Nonfinancial conflicts of interest were commonly requested; “personal ties” were specifically mentioned by nearly 40% of journals in the original sample. However, we found no publication of nonfinancial conflicts of interest in any of the issues that we obtained. Finally, 6 journals (12%) included a disclosure that referred to a time period when the conflict existed, and 3 (6%) included a disclosure that referred to the role of the funding source.

DISCUSSION

This analysis reveals a wide range of disclosure policies and practices in peer-reviewed oncology journals. Most but not all of the journals we examined required some disclosure of potential conflicts of interest, related standards and definitions varied considerably. Although both financial and nonfinancial disclosures were required, in the 104 issues we reviewed, no nonfinancial disclosures were reported.

The observation that nearly every journal in this field now includes a disclosure policy reflects a substantial evolution from past practices³⁰ and suggests that editors have taken seriously the importance of transparency of investigators’ conflicts of interest, allowing readers to make their own decisions about how such conflicts might influence the design or reporting of biomedical research. However, the practice is still not universal; 13 journals (12%) had no such policy, including 10 with Impact Factors >2.0. It is possible that the actual percentage is even higher, because 19 journals did not respond at all to our requests for a description of their disclosure policies. As we have found in previous studies in other fields, publication of disclosures for editorials and commentaries lags far behind those for reports of research.^{31,32} Such overviews may represent precisely the kind of articles that are most vulnerable to perceived or unconscious bias.

In addition to identifying important disclosure gaps in certain journals and types of articles, we also found little reporting of select types of conflicting relationships. First, it is unclear how much time must elapse until past

relationships no longer may reasonably be expected to influence behavior, although a small minority of journals provided details about the time period covered by the disclosure. Planned or future relationships may be even more relevant than those in the past, and such disclosures, although occasionally requested, were found associated with only 1 of the 1734 articles in our sample. Second, few journals required authors to disclose potential conflicts from family members or institutions, and only 6 disclosure statements in the 1734 articles we reviewed (in 4 different journals) contained any such information. These types of relationships have received comparatively less attention in the medical literature, yet examples from the government³³ and media³⁴ suggest that the relationships of one's spouse, for example, are viewed as legitimate conflicts of interest. Transparency on these conflicts may be difficult to enforce, but we believe the current landscape of widely varying requirements from journals in this field only serves to diminish the perceived importance of these conflicts to authors and readers.

We also documented wide variations in how journals define conflict of interest; relatively few described their disclosure policies in sufficient depth to help guide authors' disclosures. Many journals disclosed only rudimentary information about revealed financial relationships (ie, Dr. A is a consultant for drug company XYZ), without providing any details or measure of scale, so that a \$500 honorarium cannot be distinguished from a large annual retainer. Studies of pay-for-performance incentives for physicians document that financial incentives constituting <2% of a physician's annual income can lead to sustained changes in behavior.³⁵ Although it may be impossible to define a precise level at which financial conflicts become relevant, even arbitrarily defined thresholds could help readers evaluate the importance of disclosed relationships.

These results support the need for a more uniform depiction of conflict of interest rules in peer-reviewed journals, as well as more predictable policies concerning which of these conflicts will be published. Some organizations, such as the International Committee of Medical Journal Editors, have offered standardized disclosure statements. Any standardization efforts, however, should allow journals flexibility to adapt the disclosure policies to their particular scientific area. For example, the types of disclosures relevant to a journal focusing on basic science might be different from those relevant to a clinical science or health policy journal. There remain numerous advantages to a broader coordination of disclosure policies. One

obvious benefit would be to ensure the dissemination of minimum standards that might lead to extinguishing certain practices, such as ghostwriting, that all scientific journals should reject.³⁶ Such an effort could also help medical journals share effective practices and achieve consensus on definitions of key terms or parameters of disclosure, including time limits on past work or minimum financial thresholds. One way to develop minimum standards would be to identify which policies optimize transparency, for example by comparing authors' disclosures across different journals, or by comparing authors' disclosures to new government-mandated databases of financial relationships.³⁷ Journals could also consider organizing a central repository that could more efficiently oversee author disclosures.

We believe that standardized disclosure practices will assist readers of the medical literature in critically reading published articles, and will encourage responsible reporting by authors and journals. To accomplish the former goal, disclosed conflicts should be more consistently reported in a way that promotes clarity and assists readers. For example, we found that some journals provided disclosures extending for over a page in length that appeared to include all financial relationships, including those that may not be relevant to the topic of the article. This approach to disclosure reporting could be counterproductive if readers are not given any guidance about the importance of different disclosures. Ideally, disclosure should advance critical evaluation of study methods and conclusions, but should not lead readers to discount well-designed studies, regardless of sponsorship or authors' relationships. Small randomized studies have found that readers of articles with disclosures of conflicts show increased skepticism about articles with disclosed conflicts, as compared with articles without disclosures,^{38,39} but trials have not identified how variations in the presentation or content of the disclosure affect interpretation of the published work.⁴⁰

Another potential value of enhanced disclosure could be its effect on authors. Researchers and clinicians who are aware of basic standards for transparency may be more likely to provide evidence-based, rather than partisan, recommendations if they know their disclosures will subject them to higher scrutiny by readers. Some behavioral-psychological research has suggested that disclosure may enhance biases by giving subjects moral license to provide more extreme opinions.⁴¹ The solution is not to reduce transparency,⁴² but both to enhance transparency and to encourage accuracy through peer review, effective

editing by publishers, critical review by readers, and confirmatory testing where necessary. The *Journal of the American Medical Association*, for example, has required all industry-funded studies to undergo independent statistical testing before submission.⁴³

Our analysis has certain limitations. It is an in-depth evaluation of 1 field of medicine, potentially limiting its generalizability. It is also based on publicly available information regarding journals' policies and the disclosures printed with published articles. It is unclear whether the absence of published disclosures in certain categories (eg, for nonfinancial conflicts) reflects a lack of policy on this point by journals, a failure of disclosure by authors, or decisions by editors not to publish such disclosures. Finally, our study is a cross-sectional look at a single moment in a rapidly changing field; the articles we reviewed may have been the product of work several years prior when journals' policies were different.

Despite these limitations, our review documents substantial variation in what is requested and what is ultimately printed in oncology journals regarding authors' potential financial and nonfinancial conflicts of interest. We found frequent disclosure of stock ownership, consulting arrangements, and receipt of honoraria in oncology journal articles. Relationships with for-profit organizations have sparked intense debate within the profession and in the lay media, although such relationships can help generate and fund useful innovation. Because such relationships are common among clinicians and researchers publishing articles in oncology journals, a more coherent approach may be required to promote transparency in this rapidly evolving area.

FUNDING SOURCES

A.S.K.'s work is supported by a career development award from the Agency for Healthcare Research and Quality (K08HS18465-01) and a Robert Wood Johnson Foundation Investigator Award in Health Policy Research.

CONFLICT OF INTEREST DISCLOSURES

The authors made no disclosures.

REFERENCES

- Institute of Medicine, Board on Health Sciences Policy. Conflict of Interest in Medical Research, Education, and Practice. Washington, DC: NAS Press; 2009.
- Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. *BMJ*. 2003;326:1167-1170.
- Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. *JAMA*. 2003;289:454-465.
- Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. *Am J Psychiatry*. 2005;162:1957-1960.
- Kelly RE Jr, Cohen LJ, Semple RJ, et al. Relationship between drug company funding and outcomes of clinical psychiatric research. *Psychol Med*. 2006;36:1647-1656.
- Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. *JAMA*. 2006;295:2270-2274.
- Lesser LI, Ebbeling CB, Goozner M, Wypij D, Ludwig DS. Relationship between funding source and conclusion among nutrition-related scientific articles. *PLoS Med*. 2007;4:e5-e5.
- Leopold SS, Warme WJ, Fritz Braunlich E, Shott S. Association between funding source and study outcome in orthopaedic research. *Clin Orthop Relat Res*. 2003;415:293-301.
- Peppercorn J, Blood E, Winer E, Partridge A. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. *Cancer*. 2007;109:1239-1246.
- Sage WM. Some principles require principals: why banning "conflicts of interest" won't solve incentive problems in biomedical research. *Texas Law Rev*. 2007;85:1413-1463.
- Rowan-Legg A, Weijer C, Gao J, Fernandez C. A comparison of journal instructions regarding institutional review board approval and conflict-of-interest disclosure between 1995 and 2005. *J Med Ethics*. 2009;35:74-78.
- Bates T, Anić A, Marusić M, Marusić A. Authorship criteria and disclosure of contributions: comparison of 3 general medical journals with different author contribution forms. *JAMA*. 2004;292:86-88.
- Harris G. Cigarette company paid for lung cancer study. *N Y Times*. March 26, 2008:A1.
- Rochon PA, Gurwitz JH, Cheung CM, Hayes JA, Chalmers TC. Evaluating the quality of articles published in journal supplements compared with the quality of those published in the parent journal. *JAMA*. 1994;272:108-113.
- Citrome L. Citability of original research and reviews in journals and their sponsored supplements. *PLoS One*. 2010;5:e9876.
- Drazen JM, Van der Weyden MB, Sahni P, et al. Uniform format for disclosure of competing interests in ICMJE journals. *N Engl J Med*. 2009;361:1896-1897.
- Drazen JM, de Leeuw PW, Laine C, et al. Toward more uniform conflict disclosures—the updated ICMJE conflict of interest reporting form. *N Engl J Med*. 2010;363:188-189.
- Blum JA, Freeman K, Dart RC, Cooper RJ. Requirements and definitions in conflict of interest policies of medical journals. *JAMA*. 2009;302:2230-2234.
- Winfurt KP, Seils DM, Tzeng JP, Lin L, Schulman KA, Califf RM. Consistency of financial interest disclosures in the biomedical literature: the case of coronary stents. *PLoS ONE*. 2008;3:e2128.
- Meerpohl JJ, Wolff RF, Niemyer CM, Antes G, von Elm E. Editorial policies of pediatric journals: survey of instructions for authors. *Arch Pediatr Adolesc Med*. 2010;164:268-272.
- Hampson LA, Joffe S, Fowler R, Verter J, Emanuel EJ. Frequency, type, and monetary value of financial conflicts of interest in cancer clinical research. *J Clin Oncol*. 2007;25:3609-3614.

22. Djulbegovic B, Angelotta C, Knox KE, Bennett CL. The sound and the fury: financial conflicts of interest in oncology. *J Clin Oncol*. 2007;25:3567-3569.
23. Riechelmann RP, Wang L, O'Carroll A, Krzyzanowska MK. Disclosure of conflicts of interest by authors of clinical trials and editorials in oncology. *J Clin Oncol*. 2007;25:4642-4647.
24. Jagsi R, Sheets N, Jankovic A, Motomura AR, Amarnath S, Ubel PA. Frequency, nature, effects, and correlates of conflicts of interest in published clinical cancer research. *Cancer*. 2009;115:2783-2791.
25. Garfield E. The history and meaning of the journal impact factor. *JAMA*. 2006;295:90-93.
26. Callahan M, Wears RL, Weber E. Journal prestige, publication bias, and other characteristics associated with citation of published studies in peer-reviewed journals. *JAMA*. 2002;287:2847-2850.
27. Nakayama T, Fukui T, Fukuhara S, Tsutani K, Yamazaki S. Comparison between impact factors and citations in evidence-based practice guidelines. *JAMA*. 2003;290:755-756.
28. Kincaid JP, Fishburne RP, Rogers RL, Chissom BS. Derivation of New Readability Formulas (Automated Readability Index, Fog Count, and Flesch Reading Ease Formula) for Navy Enlisted Personnel. Memphis, TN: Naval Air Station; 1975.
29. Altman DG. *Practical Statistics for Medical Research*. London, UK: Chapman and Hall; 1991.
30. Wilkes MS, Kravitz RL. Policies, practices, and attitudes of North American medical journal editors. *J Gen Intern Med*. 1995;10:443-450.
31. Tatsioni A, Siontis GC, Ioannidis JP. Partisan perspectives in the medical literature: a study of high frequency editorialists favoring hormone replacement therapy. *J Gen Intern Med*. 2010;25:914-919.
32. Kesselheim AS, Misono AS, Lee JL, et al. The clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. *JAMA*. 2009;300:2514-2526.
33. Lichtblau E. Justice Thomas' wife sets up a conservative lobbying shop. *N Y Times*. February 4, 2011, A11.
34. Nocera J. A double standard at H.P.: editors' note. *N Y Times*. October 8, 2010. Available at: <http://www.nytimes.com/2010/10/09/business/09nocera.html> Accessed March 1, 2011.
35. Chung S, Palaniappan LP, Trujillo LM, Rubin HR, Luft HS. Effect of physician-specific pay-for-performance incentives in a large group practice. *Am J Manag Care*. 2010;16:e35-e42.
36. Give up the ghosts. *Nature*. 2010;468:732.
37. Chimonas S, Frosch Z, Rothman DJ. From disclosure to transparency: the use of company payment data. *Arch Intern Med*. 2011;171:81-86.
38. Chaudhry S, Schroter S, Smith R, Morris J. Does declaration of competing interests affect readers' perceptions? A randomised trial. *BMJ*. 2002;325:1391-1392.
39. Schroter S, Morris J, Chaudhry S, Smith R, Barratt H. Does the type of competing interest statement affect readers' perceptions of the credibility of research? A randomised trial. *BMJ*. 2004;328:742-743.
40. Silverman GK, Loewenstein GF, Anderson BL, Ubel PA, Zinberg S, Schulkin J. Failure to discount for conflict of interest when evaluating medical literature: a randomised trial of physicians. *J Med Ethics*. 2010;36:265-270.
41. Cain DM, Loewenstein G, Moore DA. The dirt on coming clean: perverse effects of disclosing conflicts of interest. *J Legal Stud*. 2005;34:1-25.
42. Cain DM, Detsky AS. Everyone's a little bit biased (even physicians). *JAMA*. 2008;299:2893-2895.
43. Wager E, Mhaskar R, Warburton S, Djulbegovic B. JAMA published fewer industry-funded studies after introducing a requirement for independent statistical analysis. *PLoS One*. 2010;5:e13591.